Veracyte, Inc. (VCYT): Revenue
$517.14M
Year ended 2025-12-31
$561.90M
Trailing 12 months to 2026-06-30
+20.4%
3-year compound annual growth
+34.5%
5-year compound annual growth
+26.4%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $517.14M | +16.0% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $445.76M | +23.5% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $361.05M | +21.8% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $296.54M | +35.1% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $219.51M | +86.8% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $117.48M | -2.4% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $120.37M | +30.8% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $92.01M | +27.9% | 2021-02-22, From 2018-01-01 |
| 2017-12-31 | $71.95M | +10.6% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $65.08M | +31.5% | 2019-02-25, From 2016-01-01 |
| 2015-12-31 | $49.50M | +29.6% | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | $38.19M | +74.5% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $21.88M | +88.2% | 2016-03-14, From 2013-01-01 |
| 2012-12-31 | $11.63M | +339.6% | 2015-03-25, From 2012-01-01 |
| 2011-12-31 | $2.65M | n/a | 2014-03-20, From 2011-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Veracyte, Inc. (VCYT) | 2025-12-31 | $517.14M | +16.0% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $379.81M | +13.8% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $344.23M | +3.7% |
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $812.03M | +97.0% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $322.67M | +13.8% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $305.11M | +100.0% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $982.02M | +32.9% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $147.17M | +17.2% |
| RadNet, Inc. (RDNT) | 2025-12-31 | $2.04B | +11.5% |
Compare VCYT, CDNA, CSTL, CAI side by side · Screen every company in Services-Medical Laboratories ↗